Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Spinogenix, Inc. announced a second grant award by the National Institute of Health (NIH). The new $3 million grant titled “Development of a Novel, Regenerative Therapy to Reverse Synapse Loss in Alzheimer’s Disease” will continue to support the development of SPG302.